Twist Bioscience (TWST) Stock Price, News & Analysis

Company Overview

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets. Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries and next-generation sequencing target-enrichment products. Twist also supports data-storage research and other emerging applications for synthetic biology.

Twist Bioscience was founded in 2013 and is headquartered in South San Francisco, California. The company serves customers globally through its commercial operations and online ordering platform. Co-founder Emily M. Leproust has served as chief executive officer since the company’s founding.

Key Stats

• Today's Range: $152.14 to $168.93
• 50-Day Range: $99.44 to $205.00
• 52-Week Range: $23.30 to $219.71
• Volume: 3.54 million shs
• Average Volume: 3.12 million shs
• Market Capitalization: $10.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $128.17
• Consensus Rating: Hold

Twist Bioscience Stock Analysis - MarketRank™

Twist Bioscience scored higher than 41% of companies evaluated by MarketBeat, and ranked 651st out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Twist Bioscience has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 2 sell ratings.

Downside Risk

Twist Bioscience has a consensus price target of $128.17, representing about 19.8% downside from its current price of $159.78.

Amount of Analyst Coverage

Twist Bioscience has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Twist Bioscience are expected to grow in the coming year, from ($2.12) to ($1.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Twist Bioscience is -71.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Twist Bioscience is -71.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Twist Bioscience has a P/B Ratio of 20.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.39% of the float of Twist Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Twist Bioscience has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Twist Bioscience has recently decreased by 15.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Twist Bioscience does not currently pay a dividend.

Dividend Growth

Twist Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.31

News Sentiment

Twist Bioscience has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Twist Bioscience this week, compared to 6 articles on an average week.

Search Interest

18 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 157% compared to the previous 30 days.

MarketBeat Follows

6 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,383,392.00 in company stock.

Percentage Held by Insiders

3.08% of the stock of Twist Bioscience is held by insiders.

Percentage Held by Institutions

Twist Bioscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TWST
• CIK: 1581280
• Web: www.twistbioscience.com
• Phone: (800) 719-0671
• Fax: N/A
• Employees: 979
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Twist Bioscience: $128.17
• High Price Target: $215.00
• Low Price Target: $41.00
• Potential Upside/Downside: -19.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.46
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.67 million
• Net Margins: -31.66%
• Pretax Margin: -31.46%
• Return on Equity: -28.64%
• Return on Assets: -19.94%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.67
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $376.57 million
• Price / Sales: 26.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.84 per share
• Price / Book: 20.38

Miscellaneous

• Outstanding Shares: 62,710,000
• Free Float: 60,776,000
• Market Cap: $10.02 billion
• Optionable: Optionable
• Beta: 2.19